Navigation Links
New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
Date:12/9/2010

f this study as we move toward personalized treatments," said principal investigator Vincent A. Miller, M.D., associate attending physician at Memorial Sloan Kettering Cancer Center, New York. "These data suggest that a certain subgroup of patients – those most likely to have EGFR mutations – may respond more positively with afatinib, and warrant further investigation."

As part of Boehringer Ingelheim's comprehensive and robust LUX clinical trial program, the phase III LUX-Lung 3 trial recently began to specifically investigate afatinib as a first-line treatment in patients with advanced NSCLC who have EGFR mutations.

About Afatinib

Afatinib is an investigational orally-administered irreversible inhibitor of both the EGFR and human epidermal receptor 2 (HER2) tyrosine kinases that is under development in several solid tumors including NSCLC, breast and head and neck cancer.  Afatinib is not approved by the FDA; its safety and efficacy have not been fully established.  

About Afatinib's Clinical Trial Program: LUX Trial Program

The LUX trial program is a comprehensive program that comprises more than 10 trials conducted across the globe, investigating afatinib in a variety of different solid tumor types, including NSCLC, breast and head and neck cancer.

LUX-Lung 1 was a phase IIb/III trial that investigated afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and first-generation EGFR-TKIs, erlotinib or gefitinib.

LUX-Lung 2 is a phase II trial evaluating afatinib in NSCLC patients with EGFR mutations, either treatment naïve or after one line of chemotherapy.

In two ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety of afatinib is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in different geographic
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Leading events organizer UBM ... for the seventh year to São Paulo, Brazil ... August 2014. The event will co-locate with Food Ingredients South ... comprehensive meeting point for the pharmaceutical industry.      ... for pharmaceutical sales are now exploring the South ...
(Date:7/25/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... second quarter 2014 financial results before the NASDAQ Global ... same day, Arena will host a conference call and ... Time). The conference call may be ... for international callers. Please specify to the operator that ...
(Date:7/24/2014)... Calif. , July 24, 2014   AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today confirmed the PDUFA date for Zalviso remains ... that a rumor circulated online stating the Food and ... 24, 2014 there has been no notification to the ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
(Date:7/25/2014)... Port Washington, NY (PRWEB) July 25, 2014 ... to protecting the rights of consumers comments on a ... the widow of a smoker $23.6 billion in punitive ... which manufactures Kool brand cigarettes. The case is Cynthia ... in 2008 in the Florida First Circuit Court, Escambia ...
(Date:7/25/2014)... July 25, 2014 Hastings and ... discount attorney’s fees with regard to personal injury claims, ... a wide range of legal services for those that ... of another individual or corporation. Free initial consultation services ... validity of a potential personal injury claim . ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- Babies seem to ... By the time women are 34 weeks pregnant, ... their mother,s voice reciting a familiar nursery rhyme, the ... source of sensory stimulation in the developing fetus," Charlene ... of Florida,s College of Nursing, said in a university ...
(Date:7/25/2014)... of Anesthesiologists (ASA) today announced the launch of ... a national initiative designed to improve the patient ... than 40 leading health care organizations from across ... will convene for the first time at the ... Schaumburg, Ill. , The PSH collaborative participants will ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 CarePoint Health ... Dr. Edward Boylan, has joined our network, CarePoint Health ... community. Hundreds of highly skilled and experienced physicians comprise ... doctors and practices in Hudson County, representing a wide ... commitment to provide the highest quality care to patients ...
Breaking Medicine News(10 mins):Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Dr. Boylan Joins CarePoint Health Medical Group 2
... Distance to care not a factor, study finds, urging greater ... News) -- Living farther away from transplant centers doesn,t explain ... apt than whites to be placed on the kidney transplant ... team that analyzed data on end-stage renal (kidney) disease patients ...
... start-ups, without forcing doctors into ... ... Corporation,today announced the pre-release of Praxis Electronic Medical Records,Version 4, featuring ... tap into the knowledge of other clinicians,enabling rapid start- ups for ...
... Nov. 9 Innovation Management Group,Inc. (IMG) announced ... 1.50, a,low cost, full screen magnification software. Most ... individuals who have extreme visual,impairments or are legally ... hundred to,several thousand dollars. The Magnifier is the ...
... at Military Bases and for Download -, PHOENIX, ... members, their families and veterans will be available,beginning Nov. ... Fighting, America Supports You, TriWest Healthcare Alliance and,many other ... "For the Troops" at 4 p.m. on,Nov. 16 at ...
... Genome Sciences,Inc. (Nasdaq: HGSI ) announced today that ... be webcast and may be accessed at, http://www.hgsi.com ... of Human Genome Sciences, senior management team will present,an ... at 4:30 pm Eastern,Time. Investors interested in listening ...
... genes associated with the Alzheimer,s ... FRESNO, Calif., Nov. 9 Consuming grapes may ... presented,this week at the Society for Neuroscience conference in ... in grapes, which,includes resveratrol, quercetin, catechins and other phytonutrients, ...
Cached Medicine News:Health News:Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 2Health News:Infor-Med, Inc. Announces New Praxis EMR Version 4 with The Praxis Knowledge Exchanger(R) 2Health News:IMG Announces an Affordable Full Screen Software Magnifier for Home and Business Users 2Health News:TriWest, Grammy-Nominated Artist and Partners Release 'For the Troops' CD in Appreciation of Military Members 2Health News:TriWest, Grammy-Nominated Artist and Partners Release 'For the Troops' CD in Appreciation of Military Members 3Health News:Eating Grapes May Protect Against Alzheimer's Disease 2
... The Clariflex® Intraocular Lens is indicated ... years of age or older in whom ... IOL is a third-generation IOL design made ... is designed both to reduce internal reflections ...
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... All USIOL lenses are manufactured ... and processes. Perspex CQ UV ... the multi-piece and single piece ... available in both nonphaco and ...
... sterile nonpyrogenic, transparent viscoelastic solution of highly ... mg/ml of high molecular weight (greater than ... physiological saline. In the limit of zero ... (105 Pa s) at 25 C and ...
Medicine Products: